Effects of Sodium Glucose Co-Transporter 2 Inhibitor Therapy on Pancreatic and hepatic fat content using 3.0 Tesla Magnetic Resonance Imaging Proton Density Fat Fraction Software in patients of Type 2 Diabetes Mellitus when treated according to current guidelines Protocol: Prospective Open Label Case Control 16 weeks Proof of Concept Study.

ASTRA ZENECA PHARMACEUTICAL INDIA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Overweight & obese (BMI 23.0 -35 kg/m2) subjects aged 20-50 years with T2DM of less than 5 year duration with HbA1c <9% & on a stable dose of metformin and/or sulphonylureas over last 8 weeks

•T2DM patients with poor glycaemic control (HbAâ??c > 9â??0%), hypoglycaemia, diabetic abscess/ulcers, ketoacidosis, pregnant or lactating women, women planning for pregnancy/gestational diabetes, cardiac and kidney disease, patients with renal transplant /undergoing immunosuppressive therapy for renal transplant ,substantial alcohol consumption ( >20 g/day for women or >30 g/day for men), Child-Pugh B/C cirrhosis, other causes of liver disease, confounding concomitant drug use (including insulin, incretin mimetics, thiazolidinediones, vitamin E), and disorders such as a medical history of pancreatitis, pancreatic lipomatosis or pancreatic calculi (as detected by ultrasonography) ,type 1 diabetes mellitus, patients requiring major drug intervention to maintain good glycemic control will be excluded

发起方

ASTRA ZENECA PHARMACEUTICAL INDIA